Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This is an investigator initiated single institution, open-label study to evaluate the
antitumor activity, safety, and tolerability of durvalumab in combination with tremelimumab
in subjects with select advanced rare solid tumors.